(USNA) USANA Health Sciences - Ratings and Ratios
Nutritional Supplements, Skincare, Personal Care, Meal Replacements
USNA EPS (Earnings per Share)
USNA Revenue
Description: USNA USANA Health Sciences October 23, 2025
USANA Health Sciences, Inc. designs, manufactures, and markets science-based nutritional, personal-care, and skincare products across the Asia-Pacific, the Americas, and Europe, positioning itself as a global wellness brand.
The business operates through two primary segments: a traditional Direct-Selling channel that relies on independent associates, and the Hiya Direct-To-Consumer segment, which emphasizes e-commerce and subscription models.
Its product portfolio includes USANA nutritional optimizers (targeting cardiovascular, skeletal, and digestive health), Essentials/CellSentials vitamin-mineral lines for children 13 months and up, meal-replacement shakes and snack bars for weight-management and energy, and the Celavive skincare regimen tailored to diverse skin types and ethnicities.
Products reach consumers via retail outlets, a subscription service, direct-selling associate networks, and online platforms, providing multiple touchpoints for customer acquisition and retention.
USANA leverages research collaborations with Beijing University of Chinese Medicine and the National Sports Training Bureau to bolster product credibility and explore novel formulations.
In FY 2023 the company generated approximately $2.3 billion in revenue, up 8 % year-over-year, with an operating margin near 10 %; its Direct-Selling segment contributed roughly 70 % of sales, reflecting the sector’s resilience amid a projected 5 % CAGR for global direct-selling revenues through 2028. Additionally, the growing consumer preference for scientifically validated supplements and clean-label personal-care products serves as a tailwind for USANA’s growth trajectory.
For a deeper, data-driven assessment of USANA’s valuation metrics and risk profile, you may find ValueRay’s analytical tools worth exploring.
USNA Stock Overview
| Market Cap in USD | 375m |
| Sub-Industry | Personal Care Products |
| IPO / Inception | 1996-07-25 |
USNA Stock Ratings
| Growth Rating | -82.2% |
| Fundamental | 57.6% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -53.5% |
| Analyst Rating | 3.0 of 5 |
USNA Dividends
Currently no dividends paidUSNA Growth Ratios
| Growth Correlation 3m | -65.1% |
| Growth Correlation 12m | -65.4% |
| Growth Correlation 5y | -94.3% |
| CAGR 5y | -28.01% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.40 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.90 |
| Sharpe Ratio 12m | -1.35 |
| Alpha | -51.93 |
| Beta | 0.605 |
| Volatility | 32.60% |
| Current Volume | 230.4k |
| Average Volume 20d | 204.1k |
| Stop Loss | 19.8 (-4.8%) |
| Signal | -0.63 |
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (34.1m TTM) > 0 and > 6% of Revenue (6% = 54.0m TTM) |
| FCFTA 0.07 (>2.0%) and ΔFCFTA -2.45pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 15.60% (prev 36.02%; Δ -20.42pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.09 (>3.0%) and CFO 63.0m > Net Income 34.1m (YES >=105%, WARN >=100%) |
| Net Debt (-151.3m) to EBITDA (96.7m) ratio: -1.56 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.15 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (18.5m) change vs 12m ago -3.25% (target <= -2.0% for YES) |
| Gross Margin 79.93% (prev 80.77%; Δ -0.84pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 131.7% (prev 138.6%; Δ -6.93pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 77.17 (EBITDA TTM 96.7m / Interest Expense TTM 848.0k) >= 6 (WARN >= 3) |
Altman Z'' 7.21
| (A) 0.19 = (Total Current Assets 261.9m - Total Current Liabilities 121.6m) / Total Assets 734.5m |
| (B) 0.65 = Retained Earnings (Balance) 474.0m / Total Assets 734.5m |
| (C) 0.10 = EBIT TTM 65.4m / Avg Total Assets 683.0m |
| (D) 3.05 = Book Value of Equity 454.7m / Total Liabilities 149.0m |
| Total Rating: 7.21 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 57.55
| 1. Piotroski 6.0pt = 1.0 |
| 2. FCF Yield 20.17% = 5.0 |
| 3. FCF Margin 5.67% = 1.42 |
| 4. Debt/Equity 0.05 = 2.50 |
| 5. Debt/Ebitda -1.56 = 2.50 |
| 6. ROIC - WACC (= -0.99)% = -1.24 |
| 7. RoE 6.42% = 0.54 |
| 8. Rev. Trend -18.15% = -1.36 |
| 9. EPS Trend -55.99% = -2.80 |
What is the price of USNA shares?
Over the past week, the price has changed by -0.43%, over one month by -28.05%, over three months by -35.18% and over the past year by -44.99%.
Is USANA Health Sciences a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of USNA is around 13.73 USD . This means that USNA is currently overvalued and has a potential downside of -33.99%.
Is USNA a buy, sell or hold?
- Strong Buy: 0
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the USNA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 39 | 87.5% |
| Analysts Target Price | 39 | 87.5% |
| ValueRay Target Price | 15.2 | -27% |
USNA Fundamental Data Overview October 15, 2025
P/E Trailing = 11.4056
P/E Forward = 11.919
P/S = 0.4172
P/B = 0.9441
P/EG = 0.9381
Beta = 0.605
Revenue TTM = 899.2m USD
EBIT TTM = 65.4m USD
EBITDA TTM = 96.7m USD
Long Term Debt = 6.01m USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 29.0m USD (from shortTermDebt, last fiscal year)
Debt = 29.0m USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -151.3m USD (from netDebt column, last quarter)
Enterprise Value = 252.8m USD (375.1m + Debt 29.0m - CCE 151.3m)
Interest Coverage Ratio = 77.17 (Ebit TTM 65.4m / Interest Expense TTM 848.0k)
FCF Yield = 20.17% (FCF TTM 51.0m / Enterprise Value 252.8m)
FCF Margin = 5.67% (FCF TTM 51.0m / Revenue TTM 899.2m)
Net Margin = 3.80% (Net Income TTM 34.1m / Revenue TTM 899.2m)
Gross Margin = 79.93% ((Revenue TTM 899.2m - Cost of Revenue TTM 180.4m) / Revenue TTM)
Gross Margin QoQ = 78.72% (prev 78.98%)
Tobins Q-Ratio = 0.34 (Enterprise Value 252.8m / Total Assets 734.5m)
Interest Expense / Debt = 0.89% (Interest Expense 259.0k / Debt 29.0m)
Taxrate = 44.50% (8.37m / 18.8m)
NOPAT = 36.3m (EBIT 65.4m * (1 - 44.50%))
Current Ratio = 2.15 (Total Current Assets 261.9m / Total Current Liabilities 121.6m)
Debt / Equity = 0.05 (Debt 29.0m / totalStockholderEquity, last quarter 531.1m)
Debt / EBITDA = -1.56 (Net Debt -151.3m / EBITDA 96.7m)
Debt / FCF = -2.97 (Net Debt -151.3m / FCF TTM 51.0m)
Total Stockholder Equity = 531.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.65% (Net Income 34.1m / Total Assets 734.5m)
RoE = 6.42% (Net Income TTM 34.1m / Total Stockholder Equity 531.5m)
RoCE = 12.17% (EBIT 65.4m / Capital Employed (Equity 531.5m + L.T.Debt 6.01m))
RoIC = 6.69% (NOPAT 36.3m / Invested Capital 543.0m)
WACC = 7.68% (E(375.1m)/V(404.1m) * Re(8.24%) + D(29.0m)/V(404.1m) * Rd(0.89%) * (1-Tc(0.44)))
Discount Rate = 8.24% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.88%
[DCF Debug] Terminal Value 75.30% ; FCFE base≈54.3m ; Y1≈47.2m ; Y5≈37.8m
Fair Price DCF = 36.36 (DCF Value 664.4m / Shares Outstanding 18.3m; 5y FCF grow -16.00% → 3.0% )
EPS Correlation: -55.99 | EPS CAGR: -57.47% | SUE: -4.0 | # QB: 0
Revenue Correlation: -18.15 | Revenue CAGR: 0.40% | SUE: 1.55 | # QB: 2
Additional Sources for USNA Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle